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million� with a median onset at 6� years� slight female 
predominance and almost invaria�le association with 
Helico�acter pylori infection. Patients typically present 
with non-specific dyspeptic type symptoms and the 
diagnosis is made gastroscopically. ��% of patients 
have Stage I/II disease.
Pathology:  The pathological appearance 
is of small- to medium-sized round or minimally irregu-
lar cells� with clumped nuclear chromatin� a�undant 
pale cytoplasm and lymphoepithelial lesions. The cells 
express pan-B markers �ut are C�5� �� and �� nega-
tive. The t���;���q��;q��� detecta�le �y FISH is pre-
sent in up to 5�% of cases with PCR-detecta�le im-
munoglo�ulin gene rearrangements in 9�% of cases. 
Management: H pylori eradication is standard 
treatment for all patients and in those with disease 
confined to the mucosa and su�mucosa results in a du-
ra�le CR in ��% of cases. For persistant or progressive 
disease chemotherapy with Chloram�ucil +/- Ritux-
ima� or loco-regional radiotherapy with �� Gy are 
standard approaches. There is no evidence that more 
intensive therapy results in a �etter outcome. Life long 
follow-up should include regular endoscopy.
Enteropathy-associated T cell lymphoma
Clinical features: Coeliac disease �C�� is caused 
�y gluten intolerance resulting in small intestinal su�-
villous atrophy and mala�sorption of varia�le severity 
which is managed with a gluten free diet �GF��. Coeliacs 
have a �� fold increased rate of developing lymphoma 
with 6���5% of them su�-typed as EATCL. Clinical pre-
sentation follows � patterns ��� development of refrac-
tory coeliac disease �RC�II� despite adherence to a GF� 
��� acute presentation with gut perforation/acute severe 
mala�sorption despite adherence to a GF� and ��� 
acute presentation as in ��� with no previous diagnosis 
of C�. EATCL diagnosis can �e challenging as it is usu-
ally confined to the small intestine and tissue is usually 
o�tained surgically or �y endoscopy �gastroscopy/
dou�le �alloon entersocopy�.  
Pathology: EATCL is characterised �y a monomor-
phic population of medium to large cells with round 
or angulated vesicular nuclei� prominent nucleoli and 
moderate to a�undant� pale-staining cytoplasm with ex-
pression of C��+� C�5+� C��+� C��+/-� C��- and C����+. 
Management: The 5 year OS is ��% with conven-
tional chemotherapy and this poor outcome is thought 
to �e related to poor patient performance status 
secondary to nutritional deficiency/gastrointestinal 
surgery and the chemo-refractoriness inherent to T-cell 
lymphomas. Outcome can �e improved using intensive 
nutritional support and primary chemotherapy followed 
�y an autologous transplantation for patients under the 
age of 65 resulting in a 5 year OS of �etween 5��6�%. 
Refractory coeliac disease: Patients who are 
diagnosed with an RC�II prodrome are interesting 
�oth for insights into EATCL lymphomagenesis and 
also �ecause they may respond to less intensive 
therapy� thus reducing the risk of EATCL transforma-
tion. RC� II is characterised �y su�-villous atrophy� 
loss of C�� intra-epithelial lymphocytes and clonal 
T-lymphocytes with ��% progression to EATCL within 
5 years. A small study of patients with RC�II who re-
sponded to Cladri�ine therapy had a 5 year OS of ��% 
which may �e improved further �y autologous SCT.
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The mature or peripheral T-cell neoplasms are 
a �iologically and clinically heterogeneous group of rare 
disorders that result from clonal proliferation of mature 
post-thymic lymphocytes. Natural killer �NK� cells are 
closely related to T cells and neoplasms derived from 
these are therefore considered within the same group. 
The World Health Organization �WHO� classification 
of haemopoietic malignancies has divided this group 
of disorders into those with predominantly leukaemic 
�disseminated�� nodal� extra-nodal or cutaneous presen-
tation. Within the WHO classification these malignancies 
are differentiated on the �asis not only of clinical features 
�ut also of morphology� immunophenotype and genetics.
The mature T-cell and NK-cell neoplasms account 
for approximately �����% of all lymphoid malignan-
cies� usually affect adults and most of the entities 
descri�ed are more commonly reported in males than 
in females. The median age at diagnosis for the group 
as a whole is 6� years with a range of ���9� years. 
There is geographical variation in the frequency of the 
different su�types and in Europe peripheral T-cell 
lymphoma� not otherwise specified �PTCL-NOS�� 
anaplastic large cell lymphoma �ALCL� and angio-
immuno�lastic T-cell lymphoma �AITL� account for 
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a�out three quarters of all cases. NK-cell lymphomas 
�NKTCL� are more common in Asia and are associated 
with Epstein-Barr virus �EBV�. The human T-cell leu-
kaemia virus �HTLV-I� is aetiologically linked to adult 
T-cell leukaemia/lymphoma �ATLL�.
Although some may follow a relatively �enign 
protracted course� most have an aggressive clinical 
�ehaviour and poor prognosis. Excluding anaplastic 
lymphoma kinase �ALK�-positive anaplastic large cell 
lymphoma �ALCL� and indolent mycosis fungoides 
�MF�� which have a good outcome� 5 year survival for 
other nodal and extranodal T-cell lymphomas is a�out 
��%. The similarity �etween progression free survival 
�PFS� and overall survival �OS� is an indication of the 
poor response to second line therapies. The rarity 
of these diseases and the lack of randomized trials 
mean that there is no consensus a�out optimal therapy 
for T- and NK-cell neoplasms.
Presentation, diagnosis, staging and progno-
sis. Extranodal presentation is common in PTCL and 
this often contri�utes to a delay in diagnosis. When 
compared to aggressive B-cell lymphomas� patients 
tend to present with unfavoura�le international prog-
nostic index �IPI� scores �> ��� more advanced disease� 
a poorer performance status and an increased inci-
dence of B symptoms. Para neoplastic features are well 
descri�ed including eosinophilia� haemophagocytic 
syndrome and autoimmune phenomena. The latter 
are particularly seen in AITL.
Diagnosis is �ased on examination of peripheral 
�lood or tissue �iopsy for histological features supple-
mented �y detailed immunohistochemistry� flow cy-
tometry� cytogenetics and molecular genetics. Expert 
haematopathology review is essential for the correct 
classification of the different su�types. Unlike B-cell 
lymphomas� there is no simple test for clonality and 
this should �e esta�lished �y polymerase chain reac-
tion �PCR� for rearrangement of T-cell receptor genes.
Staging is as for all lymphomas� including tests 
to assess the extent of disease �e.g. imaging and �one 
marrow �iopsy� and to identify the features needed 
to assign a prognostic score. Investigations include full 
�lood count and differential� tests of renal and hepatic 
function� lactate dehydrogenase �L�H�� �eta� mi-
croglo�ulin� al�umin� serum calcium� uric acid� �one 
marrow core �iopsy� chest X-ray and computerized 
tomography �CT� scan of chest� a�domen and pelvis. 
The role of l�F-fluorodeoxyglucose positron emission 
tomography �F�G-PET�/CT scanning in PTCL is under 
investigation and has only �een reported in the clinical 
evaluation of patients in a limited num�er of clinical 
studies so far. The data suggest that most T-cell lym-
phomas are F�G-avid although with varia�le intensity 
�ut that in CTCL PET is not sufficiently sensitive or spe-
cific. However� in PTCL stage was altered in less than 
��% and did not change treatment recommendations. 
It cannot �e recommended yet for routine use and 
must �e prospectively validated in trials.
Lum�ar puncture and magnetic resonance imaging 
�MRI� of the �rain are only required if there is any clinical 
suspicion of central nervous system �CNS� involvement. 
The International Prognostic Index �IPI� gives useful 
prognostic information in PTCL �ut it clusters many 
cases in the higher risk groups. Newer T-cell specific 
prognostic scores �e.g. PIT� appear to �e more dis-
criminatory and may �e valua�le in prospective trials.
Treatment. Treatment of all T and NK neoplasms 
should �e within the context of a clinical trial if pos-
si�le as standard therapy gives disappointing results. 
Outside trials� CHOP remains the standard first-line 
therapy for most nodal and extra-nodal su�types with 
no clear evidence that alternative or more intensive 
regimens are more effective. Consideration should 
�e given to consolidation with autologous haemopoiet-
ic stem cell transplantation �HSCT�� especially in high-
risk chemo-sensitive disease and AILT where results 
appear to �e superior. Relapsed or refractory disease 
should �e treated with relapse-schedule chemo-
therapy with consideration of allogeneic-HSCT �with 
reduced intensity conditioning� or autologous stem 
cell transplantation if the disease is chemosensitive. 
A num�er of newer agents show promise� particularly 
gemcita�ine �alone and in com�ination�� praletrexate 
and romidepsin. Lenalidomide� �endamustine and 
�ortezomi� have also shown efficacy.
CNS prophylaxis should �e considered using the 
same criteria as for diffuse large B-cell lymphoma.
Specific subtypes. For most su�types their rarity 
has meant that there is little evidence to determine the 
�est therapy. For some� however there is emerging 
data that specific tailored su�-type approaches are 
�eneficial� and some examples are given �elow.
T-PLL should �e treated with intravenous alem-
tuzuma� followed �y autologous or allogeneic stem 
cell transplant in first remission. Purine analogues may 
�e helpful in resistant cases.
T-LGL Leukaemia is an indolent condition which 
does not always require treatment. Therapy is in-
dicated for severe or symptomatic cytopenias and 
relies on immune-modulatory therapies such as oral 
cyclosporine� weekly oral low-dose methotrexate 
or low-dose cyclophosphamide. Second line treat-
ments include purine analogues and alemtuzuma�. 
Chronic lymphoproliferative disease of NK cells should 
�e managed as for T-LGL. Rare aggressive NK-cell 
leukaemias occurring in younger adults require a dif-
ferent therapeutic approach �ALL-type chemotherapy� 
and consideration of stem cell transplantation.
ATLL is mainly seen in far eastern �Japanese� and 
Afro-Cari��ean patients. Several su�types exist and 
the smouldering/chronic su�types may not initially 
require treatment although they may �enefit from anti-
retroviral therapy. The acute and lymphoma su�types� 
have very poor prognosis and are usually managed 
with multi-agent chemotherapy regimens followed 
�y allogeneic HSCT where possi�le. Recent evidence 
suggests that these patients �enefit from anti-viral 
drugs given concomitantly� sequentially or instead 
of chemotherapy. Novel therapies e.g. anti-CCR� are 
�eing evaluated.
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ALCL �particularly ALK+� has the �est outcome with 
conventional CHOP. Relapsed patients have achieved 
very high response rates with a C���-targeted immune-
conjugate� �rentuxima� vedotin. This may �e effective 
in other C���-positive PTCL and is currently �eing 
evaluated in com�ination in the front-line setting. 
Extranodal Nasal NK/T cell lymphoma occurs 
most commonly in Asian populations and is EBV posi-
tive. The distinction at diagnosis �etween localized and 
disseminated disease is important as the latter has 
a dismal prognosis. Outcome is unsatisfactory with 
CHOP-like therapy and asparaginase-containing 
regimens are preferred. High dose radiotherapy 
�5��55 Gy� is very important in the control of localized 
disease and contri�utes significantly to cure of patients 
with limited stage at presentation.
EATL patients often present acutely and with 
poor PS. It is important to liaise with an experienced 
gastroenterologist to assist with �iopsy� staging and 
follow up and to manage nutritional pro�lems. CHOP-
like or intensified therapy� with an up-front autograft 
remains a common approach and does appear 
to �e superior to CHOP alone in retrospective series.
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